If you are weighing up treatment in China from the US, the UK, Australia or continental Europe, almost every line of enquiry ends at the same place: is the medical equipment in Chinese hospitals actually on par with what I would get at home? It is a reasonable question, and unlike most questions in medical travel it has a documentary answer. China's drug and device regulator, the National Medical Products Administration (NMPA), publishes a monthly announcement listing every medical device product it has registered. For September 2026, that announcement covered 258 products, and 44 of those registrations went to imported devices — a figure reported by China Pharmaceutical News on 16 October 2026 from the regulator's own website.
You do not need to become a regulatory analyst to use that. What you need is a narrow, checkable question and about an hour of work. This article shows you both.
First, sharpen the question
"Is the equipment world-class?" cannot be answered, and anyone who answers it is selling you something. Two narrower questions can be answered with paperwork:
- Is the specific device or software my plan depends on registered for use in China?
- Does the department I will actually attend run that model, for my indication?
These are different facts. The first is a market authorisation held by a manufacturer. The second is a procurement and staffing reality at one hospital on one corridor. International patients routinely confirm one and assume the other, which is how disappointment starts.
Note also what equipment parity is not. It is one input among several — clinician experience, case volume, protocol, nursing support and follow-up all carry weight. And no device registration is a statement about results for your disease. Whether any of this applies to you has to be assessed in person by a licensed physician who has read your records; nothing here substitutes for that consultation.
What the September 2026 NMPA bulletin actually says
The announcement carries the reference number 2026 No. 101 and covers devices registered during September 2026. Its composition is the part worth reading slowly:
| Category in the September 2026 announcement | Count | Why an overseas patient should care |
|---|---|---|
| Domestic Class III (highest-risk) devices | 212 | Chinese manufacturers cleared high-risk product at volume |
| Imported Class III devices | 22 | Foreign-made high-risk products authorised for use in China |
| Imported Class II devices | 22 | Mid-risk imports — the band that covers much diagnostic and monitoring hardware |
| Products from Hong Kong, Macao and Taiwan | 2 | Small, but shows a distinct regulatory lane exists |
| Total for the month | 258 | One month only, not a running annual total |
Two things follow from this, and no more than these. First, imports were not a rounding error: roughly one registration in six that month went to a foreign manufacturer, across both the highest and middle risk classes. Second, the cadence is monthly. The regulator keeps a steady flow of new registrations, including imported ones, which is why a check performed in 2023 can be out of date today.
What the list does not do is rank hospitals, certify a department's competence, or imply that every machine in every Chinese hospital matches a machine in Cleveland or Melbourne. It is a registry. Treat it as one.
A timeline you can work backwards from
The verification is worth starting six to eight weeks before you fly, because its output changes what you ask the physician.
| When | What to do | What you should be holding afterwards |
|---|---|---|
| Before contacting anyone | Assemble your clinical file: imaging on disc plus reports, pathology, operative notes, discharge summaries, current medication list | One complete, dated record set you can share |
| 6–8 weeks out | Open the conversation with the Chinese hospital or department; ask what modality and what named device or software their plan relies on | Device type, manufacturer, model, software version, in writing |
| 5–6 weeks out | Run the NMPA lookup on those details | A registration certificate number — or a clear "not found" to take back |
| 4–5 weeks out | Ask the site to confirm the certificate covers your indication and that the department runs that model day-to-day | Written confirmation, or the absence of it |
| 3–4 weeks out | Send records plus your verification notes for physician review | A plan you can compare against what you were told at home |
| At booking | Confirm costs with the hospital, arrange visa documents, book interpreter support | An itemised quote from the hospital and a dated itinerary |
The cost line sits last deliberately. Prices for any given procedure are set by the hospital after it reviews your records, and they are not published in this article because we will not quote a number you cannot use.
Step 1 — get the name out of marketing and into a specification
Ask for the generic device name, the manufacturer, the model number and, for software or AI-assisted imaging tools, the version. "The linear accelerator we use" is not a specification; a model number is. If a department resists giving one, note that.
Step 2 — search the NMPA records, and expect Chinese
Searches against the regulator's device database and its monthly announcements work best with the Chinese product name, because that is how registrations are filed. Practical consequences: a translation of the device name usually beats the English brand, and a certificate number is unambiguous where a brand name is not. If you work in English only, this is the single most useful thing to hand to a coordinator or interpreter.
Step 3 — read class and origin, not the press release
Class III indicates higher risk and a more demanding review path than Class II; imported and domestic products travel separate lanes, which is why the September list splits 22 imported Class III from 212 domestic Class III. A product can be legitimately registered as a Chinese-manufactured version of a foreign design, which is not the same as an import under a foreign certificate. Ask which you are looking at.
Step 4 — confirm it is on your corridor
Certificates are held by manufacturers. Ask the department whether the registered model is installed where you will be treated, whether it is maintained and in routine clinical use, and whether your specific indication falls inside what the registration covers. This is where proton and other high-capital radiotherapy questions usually get settled, because a single gantry room is not fungible with a centre.
Step 5 — carry the result into the consultation
Bring a one-page summary: device, model, certificate number, source, date checked, and what remains unconfirmed. It makes the physician's answer more specific and gives you a paper trail. It also lets you compare two centres on something other than photographs of their lobby.
Where this check matters most
Radiotherapy and particle therapy. Equipment identity is the whole question in radiation oncology. A useful, time-sensitive example: capacity in the Greater Bay Area is still growing. A Shenzhen proton therapy centre opened on 8 August 2025 and, per an update published by the Shenzhen Municipal Health Commission, completed enrolment of its final clinical-trial patient on 8 January 2026, with study data to be submitted to the NMPA after three-month follow-up. That update is explicit that routine clinical use depends on a licence approval, and its core facilities include both rotating-gantry and fixed-beam treatment rooms. Read that the right way: as of that notice the centre was in trial phase, not open for unrestricted routine care. If proton therapy is on your plan, ask the centre for its current status, its international-patient schedule and its quotation, rather than relying on any third-party summary — ours is here and our coordination service is at proton therapy in China.
Cell-based and software-driven therapies. Where a plan involves CAR-T or similar products, what you are buying is a programme at a named site, not a machine in a room — so ask which product, under which authorisation, at which hospital. Our pages on CAR-T therapy in China and on CAR-T costs cover how that is structured. For diagnostic software and imaging AI, the same registration logic as above applies, and it is worth checking whether the version you were scanned on at home exists in China at all.
What a registration certificate does not tell you
- It is not a quality league table for hospitals.
- It does not prove the machine is installed, working or staffed at your site.
- It carries no price and no reimbursement ruling.
- It says nothing about outcomes for your condition, and no responsible source will quote you a cure rate.
- One month's announcement is a snapshot, not a trend line.
For the hospital-selection layer that sits above all of this, start with how we shortlist hospitals and, if Shanghai is your entry point, the international-hospital landscape there.
Three other things to line up at the same time
A device check is one of several documents-based tasks that all want doing before travel. Book the specialist appointment with enough lead time — see hospital appointment support in Shanghai. Sort the medical visa and its supporting letters using our China medical visa guide. Consider a baseline health checkup if your own recent numbers are out of date; this walkthrough for expats in Shanghai explains what a Chinese checkup includes. For the wider picture on treatment in China, the complete medical tourism guide and cancer treatment in China are the two starting points most patients use.
Want someone to run the check for you?
The lookup itself is short. The awkward parts are the Chinese-language product names, getting a certificate number out of a busy department, and knowing when an answer is evasive. That is ordinary coordination work, and it is what we do.
OriEast provides document translation, hospital appointments, and day-to-day coordination for international patients in China — including verifying whether the technology named in your proposed plan is registered here, before you commit to travel. Send your records through case evaluation and we will review what the plan actually depends on, or ask us directly via inquiry. Your clinical decisions stay with your physicians; the paperwork stops being a guess.